Keith W. Crawford, R.Ph., Ph.D. HIV Faculty Expert
|
|
- Lee Wells
- 5 years ago
- Views:
Transcription
1 Keith W. Crawford, R.Ph., Ph.D. HIV Faculty Expert
2 Sponsor Accreditation: Howard University College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credits for Physicians: Howard University College of Medicine, Office of Continuing Medical Education, designates this live activity for a maximum of 0.5 AMA PRA Category I Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Goulda A. Downer, PhD, RD, LN, CNS Principal Investigator/Project Director Funded by Health Resources Services Administration (HRSA) Grant #H4AHA24081
3 AETC-Capitol Region Telehealth Project Planning Committee : The following committee members have nothing to disclose in relation to this activity: Goulda A. Downer, PhD, RD, LN, CNS Denise Bailey, MEd Marjorie Douglas-Johnson, BA Kwame Frimpong Speaker: The following speaker has nothing to disclose in relation to this activity: Keith W. Crawford, R Ph, PhD
4 Intended Audience: Low volume clinicians (i.e. those with fewer than 25 patients in their case load who are HIV positive): Physicians, Physician Assistants, Nurse Practitioners, Pharmacists, Dentists, Nurses, Social Workers, Case Managers and other Clinical Personnel. Webinar Requirements: A computer, phone, etc., with Internet accessibility and a telephone line. Your presence on the call must be acknowledged at the start of each session. Please log in for the session then announce your name loudly and clearly at the beginning of the session. You will not be able to receive CME credit if you leave the session early. At the end of the Webinar our Training Coordinator will a CME Evaluation Survey. All participants are required to complete and return the CME Evaluation Survey at the end of each session. It may be scanned and ed back to mdouglas@howard.edu, or faxed to: AETC-Capitol Region Telehealth Project (FAX#: ) ATTN: Training Coordinator. Please indicate in your or FAX if you would like to receive CME credit.
5
6 A subject presents to the ER for testing suspecting they may have acute HIV infection. What single test would be most useful in determining this? A. A viral load (HIV RNA) B. A western blot C. A fourth-generation HIV test D. A home HIV test
7 Which statement is correct? A. Population-based treatment of symptomatic and asymptomatic urethritis has been shown to reduce HIV incidence B. An additional advantage of treating bacterial vaginosis is that it increases CD4+ cell count in HIV patients not on antirtroviral therapy C. Successful treatment of most STI's will result in a reduction of HIV in semen and vaginal fluid D. HSV-2 infection increases the acquisition of HIV from female to male but not from male to female E. All statements are correct
8 The most effective agent as a topical microbicide is: A. Topical AZT (zidovudine creme) B. A topical gel containing the spermicide nonoxynol-9 C. Tenofovir gel D. Carraguard gel E. They are all equally effective
9
10 Upon completion of this webinar, participating providers will have the enhanced ability to: Discuss CDC guidelines for non-occupational HIV post-exposure prophylaxis (n-pep) Discuss timing of Post Exposure Prophylaxis treatment initiation Describe post-exposure prophylaxis therapy and side effects State challenges associated with Post Exposure Prophylaxis Explain transmission risks for various n-pep exposures Understand the dynamics of HIV transmission and early infections and select tests likely to be most accurate based on the subject s stage of infection Assess the level of risk of transmission for a patient presenting for npep 10
11 Scott, a 19-year-old who was visiting his cousin Matt at a local college campus decided to attend a party given by a graduate student Before leaving for the party, at 10:00 PM, Matt warned Scott to stick to punch or sodas and not to drink any alcoholic beverages He also advised him not to leave his drink unattended Scott promised and consumed a total of three glasses of fruit punch; He did not consume any alcohol At 3:00 AM when the party was winding down and Matt was ready to go home he was unable to locate his young cousin Scott was found unconscious at about 3:45 AM lying in a fetal position; He was nude from the waist down and bleeding from his rectum There was also evidence of vomitus and bruise on his left cheek The police were called and Scott was rushed to the emergency room Two hours later, Matt was told that Scott was raped and did not want to see him or anyone else. From HU CRTP Case Study Bank
12
13 Receptive or insertive vaginal or anal sex Sharing needles for drug-use Injuries with exposure to blood or other high-risk fluids from a person known to be HIV+ or of unknown status npep is NOT indicated for low-risk exposures!
14 Tenofovir/Emtricitibine Plus Raltegravir or Dolutegravir Boosted protease inhibitor Atazanavir (300/100) or Darunavir (800/100) Treatment should be initiated ideally with 36 hours of exposure, certainly with 72 hours, and continued for 28 days
15 Perform baseline testing Perform testing of the source (if possible) Test subject at baseline, week four postexposure and week 12
16 Clinical chemistries for monitoring patients on ART at baseline, week 2 and 4 post-exposure -liver enzymes, BUN, creatinine, CBC Test for other STI s at baseline - gonorrhea/chlamydia NAAT - syphilis RPR HCV/HBV Pregnancy test
17
18 Male Circumcision as a Strategy for Reducing HIV Transmission Risk
19 The foreskin contains a mucosal surface on the penis This mucosal surface can be a gateway for pathogens, particularly sexually-transmitted ones, into the body Dendritic cells and other APC s maintain surveillance for pathogens that breach the foreskin mucosal surface Dendritic cells that encounter HIV can carry the virus almost in a Trojan Horse style to infect T lymphocytes in lymphoid tissues Three RCT demonstrate efficacy of male circumcision in reducing risk of HIV transmission by 50-60%
20
21 Figure 2 Source: The Lancet 2007; 369: (DOI: /S (07) ) Terms and Conditions
22 Figure 2 Source: The Lancet 2007; 369: (DOI: /S (07) ) Terms and Conditions
23 TABLE 1. Voluntary medical male circumcisions (VMMCs) performed by CDC-supported programs, by country and fiscal year, Country No. of VMMCs Total Botswana 8,590 8,590 Kenya* 104, , , ,752 Malawi 778 7,420 8,198 Mozambique 4,009 18,472 68,924 91,405 Namibia 1,197 5,292 5,965 12,454 South Africa 3,820 15,574 80, ,095 Tanzania 1,519 50,325 49, ,600 Uganda 9,052 57, , ,812 Zambia 13,368 33,841 58, ,518 Total 137, , ,604 1,020,424 Source: President's Emergency Plan for AIDS Relief (PEPFAR) annual progress report (APR) submissions for CDC-supported partners, for fiscal years October 1 September 30, except where noted. * Kenya's data for 2010 and 2011 are reported from January December, but data from 2012 are from October September. Malawi's data are from APR results and CDC Malawi's partner reports for South Africa's data are reported from January December for Tanzania's data for are from APR reports and Tanzania's national database.
24 HSV-2? Chlamydia? Gonorrhea? Trichomonas vaginalis? High-risk and low-risk HPV genotypes!
25
26 STI s result in inflammation and migration of immune cells into the genital tract. Inflammatory cytokines increase HIV replication and make immune cells more susceptible to HIV infection Genital Ulcer Disease (GUD) caused by STI s (HSV- 1,2, syphilis) compromise the integrity of the mucosal barrier and facilitate HIV transmission
27 STI s (e.g. gonorrhea) can increase the amount of HIV in semen and vaginal fluids up to 10x increasing exposure to the partner Reproductive Tract Infections (RTI; bacterial vaginosis, Trichomonas) increase HIV in vaginal fluids and risk of transmission STI s and RTI s increase the risk of HIV transmission from seropositive individuals and also HIV acquisition by a seronegative individual
28 HIV-1-seropositive men with urethritis had HIV-1 RNA concentrations in seminal plasma eight times higher than those in seropositive men without urethritis (12.4 vs 1.51 x 10 4 copies/ml, p = 0.035). CD4 counts and concentrations of blood plasma viral RNA were similar Gonorrhoea was associated with the greatest concentration of HIV-1 in semen Treatment of STI decreased the concentration of HIV-1 RNA in semen significantly (from 12.4 x 10 4 copies/ml to 8.91 x 10 4 copies/ml at 1 week [p = 0.03] and 4.12 x 10 4 copies/ml at 2 weeks [p = ]) Cohen et al., Lancet,2007,349(9069):
29 A causative agent of genital ulcer disease HSV-2 is suspected to be a major driver of the HIV epidemic in Africa
30 The Effect of Valacyclovir on Postpartum Plasma (A) and Breast Milk (B) Human Immunodeficiency Virus Type 1 (HIV-1) RNA Levels Drake A L et al. J Infect Dis. 2012;205:
31 Effect of Valacyclovir Treatment on HIV RNA Levels in Rectum and Plasma in Co-Infected MSM s (in Co-Infected B) HIV-1 Levels between Treatment Arms, by Individual Participant 2007 by the Infectious Diseases Society of America Zuckerman R A et al. J Infect Dis. 2007;196:
32
33
34 Lactobacillus sp. predominate in the vaginal normal flora Bacterial vaginosis is characterized by alterations in the vaginal microbiome and colonization by species like Gardnarella vaginalis, Mycoplasma hominis BV increases vaginal inflammation and increases shedding of HIV into cervicovaginal fluid
35 Incidence of HIV-1 Transmission to Men, by the Vaginal Flora Category of their Female HIV-1 Infected Partner Cohen CR, Lingappa JR, Baeten JM, Ngayo MO, et al. (2012) Bacterial Vaginosis Associated with Increased Risk of Female-to- Male HIV-1 Transmission: A Prospective Cohort Analysis among African Couples. PLoS Med 9(6): e doi: /journal.pmed
36 STI/RTI facilitate HIV transmission Treatment of STI s/rti s reduce the concentration of HIV in semen and vaginal fluids Treatment of some STI s may also reduce the concentration of HIV in plasma (e.g. HSV-2) Reducing the concentration of HIV in genital fluids and plasma should reduce HIV transmission Amazingly, population-targeted interventions in treating symptomatic and asymtomatic STI s/rti s have not shown an effect in reducing HIV incidence
37 Topical Microbicides
38 Topical microbicides are formulations (gels, creams, devices) that are applied/inserted vaginally or rectally to prevent infections from agents like HIV. They are designed to protect the receptive partner. They may: Kill or inactivate the pathogen (e.g. detergents) Create a barrier preventing the pathogen crossing the mucosa Pharmacologically target the pathogen preventing replication in or spread from mucosal tissues
39 TRIAL MICROBICIDE N COUNTRIES EFFECT Abdool Karim 2011 BufferGel 1546 Malawi, South Africa, United States, Zambia, Zimbabwe RR 1.05, 95% CI 0.73 to 1.52 Skoler-Karpoff 2008 Carraguard 6202 South Africa RR 0.89, 95% CI 0.71 to 1.11 Halpern 2008, Van Damme 2008 CS 3069 Benin, India, Nigeria RR 1.20, 95% CI 0.74 to 1.95 Abdool Karim 2011, McCormack 2010 PRO Malawi, South Africa, Tanzania, Uganda, United States, Zambia, Zimbabwe RR 0.93, 95% CI 0.77 to 1.14 Feldblum 2008, Peterson 2007 SAVVY (C31G) 4295 Ghana, Nigeria RR 1.38, 95% CI 0.79 to 2.41 Abdool Karim 2010 TDF 889 South Africa, Uganda, Zimbabwe RR 0.63, 95% CI 0.43 to 0.93
40 # HIV infections / women years Tenofovir Placebo Overall effectiveness of tenofovir gel HIV 38 / 60 / endpoints N HIV incidence Tenofovir gel (95% CI) 5.6 (4.0, 7.7) Placebo gel (95% CI) 9.1 (6.9, 11.7) Incidence Rate Ratio Effectiveness 95% Confidenc e Interval p- value % 6, HIV endpoints by levels of adherence^ High adherers 25 / (>80% gel 11 / adherence) Intermediate adherers (50-80% adherence) Low adherers (<50% gel adherence) 10 / / / / (2.1, 7.6) 6.3 (3.0, 11.5) 6.2 (3.5, 10.1) 9.3 (6.0, 13.7) 10.0 (4.8, 18.4) 8.6 (5.6, 12.7) % 4, % -67, % -40,
41 # HIV infections /women years T Tenofovir Placebo N Tenofovir gel (95% CI) HIV incidence Overall effectiveness of tenofovir gel HIV endpoints 38 / / (4.0, 7.7) Placebo gel (95% CI) 9.1 (6.9, 11.7) Incidence Rate Ratio Effectivenes s 95% Confidenc e Interval p- value % 6, Effectiveness of tenofovir gel by study exit HSV-2 status HSV-2 positive 29 / / (4.9, 10.5) 11.2 (8.2, 14.9) % -6, HSV-2 negative 9 / / ( 1.5, 6.3) 5.6 (3.1, 9.5) % -45,
42
43 Scott, a 19-year-old who was visiting his cousin Matt at a local college campus decided to attend a party given by a graduate student Before leaving for the party, at 10:00 PM, Matt warned Scott to stick to punch or sodas and not to drink any alcoholic beverages He also advised him not to leave his drink unattended Scott promised and consumed a total of three glasses of fruit punch; He did not consume any alcohol At 3:00 AM when the party was winding down and Matt was ready to go home he was unable to locate his young cousin Scott was found unconscious at about 3:45 AM lying in a fetal position; He was nude from the waist down and bleeding from his rectum There was also evidence of vomitus and bruise on his left cheek The police were called and Scott was rushed to the emergency room Two hours later, Matt was told that Scott was raped and did not want to see him or anyone else. From HU CRTP Case Study Bank
44
45 Sensitivity and specificity of home HIV tests Proper use and interpretation of results Detection of acute HIV infection by rapid tests Is the subject a candidate for npep?
46 UPDATE: HIV Prophylaxis Following Non-Occupational Exposure tional_post_exposure_prophylaxis_in_new_york (video) Pre Exposure Prophylaxis for the Prevention of HIV Infection in the United States -2014: A Clinical Practice Guideline (US Public Health Service) HIV Post-Exposure Prophylaxis for Occupational and Non-occupational Exposure normal
47
48 A subject presents to the ER for testing suspecting they may have acute HIV infection. What single test would be most useful in determining this? A. A viral load (HIV RNA) B. A western blot C. A fourth-generation HIV test D. A home HIV test
49 Which statement is correct? A. Population-based treatment of symptomatic and asymptomatic urethritis has been shown to reduce HIV incidence B. An additional advantage of treating bacterial vaginosis is that it increases CD4+ cell count in HIV patients not on antirtroviral therapy C. Successful treatment of most STI's will result in a reduction of HIV in semen and vaginal fluid D. HSV-2 infection increases the acquisition of HIV from female to male but not from male to female E. All statements are correct
50 The most effective agent as a topical microbicide is: A. Topical AZT (zidovudine creme) B. A topical gel containing the spermicide nonoxynol-9 C. Tenofovir gel D. Carraguard gel E. They are all equally effective
51 Howard University HURB th Street NW, 2 nd Floor Washington, DC (Office) (Fax) As a Reminder: At the end of the Webinar, participants are required to complete and return the CME Evaluation Survey. It may be scanned and ed back to mdouglas@howard.edu, or faxed to: AETC-Capitol Region Telehealth Project (FAX#: ) ATTN: Training Coordinator. Please indicate in your or FAX if you would like to receive CME credit.
BIOMEDICAL PREVENTION: NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (NPEP) GUIDELINES
BIOMEDICAL PREVENTION: NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (NPEP) GUIDELINES ORLANDO O. HARRIS, PHD, RN, FNP, MPH POST-DOCTORAL FELLOW, CENTER FOR AIDS PREVENTION STUDIES, DEPARTMENT OF MEDICINE
More informationSTRATEGIES TO REDUCE HIV INFECTION AMONG HBCU COLLEGE STUDENTS
STRATEGIES TO REDUCE HIV INFECTION AMONG HBCU COLLEGE STUDENTS ORLANDO O. HARRIS, PhD, RN, FNP, MPH FELLOW CENTER FOR AIDS PREVENTION STUDIES (CAPS) DEPARTMENT OF MEDICINE UNIVERSITY OF CALIFORNIA, SAN
More informationOutline. HIV and Other Sexually Transmitted Infections. Gonorrhea Epidemiology. Epidemiology 11/2/2012
HIV and Other Sexually Transmitted Infections Tanya Kowalczyk Mullins, MD, MS Division of Adolescent Medicine Cincinnati Children s Hospital Medical Center Outline Epidemiology of select STIs and HIV STIs
More informationIsabel Rambob, DDS Assistant Professor University of Maryland School of Dentistry
Isabel Rambob, DDS Assistant Professor University of Maryland School of Dentistry Sponsor Accreditation: Howard University College of Medicine is accredited by the Accreditation Council for Continuing
More informationUpdate on ARV based PrEP
Update on ARV based PrEP Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw Controlling HIV
More informationBIOMEDICAL PREVENTION: NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (NPEP)
BIOMEDICAL PREVENTION: NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (NPEP) ORLANDO O. HARRIS, PhD, RN, FNP, MPH POSTDOCTORAL FELLOW, CENTER FOR AIDS PREVENTION STUDIES, DEPARTMENT OF MEDICINE UNIVERSITY
More informationHIV TRANSMISSION AND PREVENTION KENNETH H. MAYER, M.D. BROWN UNIVERSITY/MIRIAM HOSPITAL FENWAY COMMUNITY HEALTH 5/31/07
HIV TRANSMISSION AND PREVENTION KENNETH H. MAYER, M.D. BROWN UNIVERSITY/MIRIAM HOSPITAL FENWAY COMMUNITY HEALTH 5/31/07 Estimates of Per-Contact Risk of HIV Infection HIV TRANSMISSION SIGNIFICANT, LOW
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationThe Synergy between HIV and other STIs
Training Course in Sexual and Reproductive Health Research 2017 Module: Sexually transmitted infections, HIV/AIDS The Synergy between HIV and other STIs Alberto Matteelli Brescia University Sexual Transmission
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationGUIDELINES ON INCORPORATING HIV PREVENTION INTO MEDICAL CARE
GUIDELINES ON INCORPORATING HIV PREVENTION INTO MEDICAL CARE JOHN I. MCNEIL, MD, FACP MAXIMED ASSOCIATES MARYLAND JANUARY 26, 2017 CME Disclosures: Planning Committee And Speaker Speaker: The following
More informationSexually Transmitted Infection Treatment and HIV Prevention
Sexually Transmitted Infection Treatment and HIV Prevention Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine STI Treatment and HIV Prevention.
More informationDisclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.
Disclosure PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION I have no financial interest in and/or affiliation with any external organizations in relation to this CE program. DaleMarie Vaughan, PharmD
More informationProfessor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA
17 TH ANNUAL CONFERENCE OF THE BRITISH HIV ASSOCIATION (BHIVA) Professor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA 6-8 April 2011, Bournemouth International Centre 17 TH ANNUAL
More informationCARE FOR PATIENTS WITH CHRONIC HCV/HIV COINFECTIONS
CARE FOR PATIENTS WITH CHRONIC HCV/HIV COINFECTIONS JOHN I. MCNEIL, MD, FACP MAXIMED ASSOCIATES MARYLAND JUNE 8, 2017 CME Disclosures: Planning Committee And Speaker Speaker: The following speaker has
More informationHIV Prevention. Recent Advances and Implications for the Caribbean
HIV Prevention Recent Advances and Implications for the Caribbean Chris Behrens, MD CCAS/CHART Conference Barbados, August 2010 Cases 200 180 160 140 120 100 80 60 40 20 0 Year HIV Cases AIDS Cases HIV
More informationPost-Sexual Exposure Prophylaxis (npep)
Projeto Praça Onze Universidade Federal do Rio de Janeiro Post-Sexual Exposure Prophylaxis (npep) Mauro Schechter Principal Investigator, Projeto Praça Onze Professor of Infectious Diseases Universidade
More informationDoing studies of ARV based
Doing studies of ARV based microbicides what s s different, what s s the same? Gonasagrie Nair, MBChB, DTM&H, MPH CAPRISA ethekwini Site Project Director & IoR VOICE Trial OVERVIEW Brief historical overview
More informationPrEP for HIV Prevention. Adult Clinical Guideline from the New York State Department of Health AIDS Institute
PrEP for HIV Prevention Adult Clinical Guideline from the New York State Department of Health AIDS Institute www.hivguidelines.org Purpose of the PrEP Guideline Raise awareness of PrEP among healthcare
More informationInspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel
Inspiring HIV Prevention Innovations for Women IPM Satellite Event Durban, 13 th June 2017 Annalene Nel HIV Infection: Where We Are Today 30+ years since the US CDC reported the first cases of AIDS 25.5
More informationHIV Prevention Strategies HIV Pre-exposure prophylaxis
HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those
More informationSexually Transmitted Infections in Vulnerable Groups. Kevin Rebe
Sexually Transmitted Infections in Vulnerable Groups Kevin Rebe Definition: Key Populations Key populations are: Defined groups who, due to specific higher-risk behaviours, are at increased Men risk who
More informationART for HIV Prevention:
ART for HIV Prevention: KENNETH H. MAYER, M.D. Brown University/The Fenway Institute August 22, 2009 APPROACHES TO PREVENT HIV TRANSMISSION DECREASE SOURCE OF INFECTION Barrier Protection Treat STI Antiretroviral
More informationThe Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN
The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure
More informationFertility Desires/Management of Serodiscordant HIV + Couples
Fertility Desires/Management of Serodiscordant HIV + Couples William R. Short, MD, MPH Assistant Professor of Medicine Division Of Infectious Diseases Jefferson Medical College of Thomas Jefferson University
More informationIn July 2011, FHI became FHI 360.
In July 2011, FHI became FHI 360. FHI 360 is a nonprofit human development organization dedicated to improving lives in lasting ways by advancing integrated, locally driven solutions. Our staff includes
More informationHIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
More informationCARE FOR PATIENTS WITH CHRONIC HCV/HIV COINFECTIONS
CARE FOR PATIENTS WITH CHRONIC HCV/HIV COINFECTIONS JOHN I. MCNEIL, MD, FACP MAXIMED ASSOCIATES MARYLAND APRIL 26, 2018 CME Disclosures: Planning Committee And Speaker Speaker: The following speaker has
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationWhat Do We Really Mean By Adherence in Vaginal Microbicide Trials?
What Do We Really Mean By Adherence in Vaginal Microbicide Trials? A COMPARATIVE STUDY International Conference on HIV Treatment and Prevention Adherence June 9 th, 2014 Miami, USA Lori Miller, MHS PhD
More informationPrEP: Pre Exposure Prophylaxis
PrEP: Pre Exposure Prophylaxis Lyn Stevens, NP, MS, ACRN Deputy Director Office of the Medical Director NYS Department of Health, AIDS Institute Faculty Disclosure Lyn Stevens No relationships to disclose
More informationAntiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?
Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated
More informationRecent Breakthroughs in HIV Prevention for Men who Have Sex with Men and Transgender Populations
Recent Breakthroughs in HIV Prevention for Men who Have Sex with Men and Transgender Populations Kevin Ard, MD, MPH Brigham and Women s Hospital The Fenway Institute Boston, MA Funding: The New England
More informationPrEP and Behavioral Strategies for HIV Prevention. Douglas Krakower, MD January 30, 2014
PrEP and Behavioral Strategies for HIV Prevention Douglas Krakower, MD January 30, 2014 Potential Competing Interests Dr. Krakower: investigator-initiated research regarding HIV prevention National Institutes
More informationIt is a good idea for anyone having sex to get tested regularly and treated for STIs if necessary.
FACTSHEET Sexually Transmitted Infections and HIV Transmission This is one of a series of fact sheets about the biology of HIV transmission. The fact sheets review specific biological factors that make
More informationPEP and PrEP: AWAAC 2014
Acknowledgements: HIVCS PEP guidelines group, Helen Rees, Slim Abdool Karim, Quarraisha Abdool Karim, Clinical Care Options, Edwina Wright, Jared Baeton, AETC PEP and PrEP: AWAAC 2014 Francois Venter Wits
More informationTransmission Networks & Risk of HIV Infection in Young Women in KwaZulu-Natal, South Africa
Transmission Networks & Risk of HIV Infection in Young Women in KwaZulu-Natal, South Africa FIDSSA, Cape Town, November 2017 Quarraisha Abdool Karim, PhD Associate Scientific Director: CAPRISA Professor
More informationRoy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
More informationFAMILY HIV CENTER NJ CARES SANE
HIV, Hepatitis B & C Postexposure Prophylaxis for Sexual Assault Victims Update for Case Managers Susan Burrows-Clark, RN, MSN, CNS, C. 10/17/11 Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug
More informationWhat s new in sexually-transmitted infections?
What s new in sexually-transmitted infections? Kevin L. Ard, MD, MPH National LGBT Health Education Center, Fenway Institute Infectious Disease Division, Massachusetts General Hospital Director, Genitourinary
More informationART FOR HIV PREVENTION: PANACEA OR PANDORA S BOX? KENNETH H. MAYER, M.D.
ART FOR HIV PREVENTION: PANACEA OR PANDORA S BOX? KENNETH H. MAYER, M.D. HIV TRANSMISSION SIGNIFICANT, LOW PROBABILITY EVENT (
More informationPrEP efficacy the evidence
PrEP efficacy the evidence Dr Michael Brady Consultant, HIV and Sexual Health King s College Hospital, London Medical Director Terrence Higgins Trust PrEP Pre-exposure prophylaxis Tenofovir and emtricitabine
More informationGetting Prepped for PrEP. Ken Ho, MD, MPH World AIDS Day
Getting Prepped for PrEP Ken Ho, MD, MPH World AIDS Day Objectives HIV epidemiology What is PrEP? Does it Work? Who gets PrEP? How do I prescribe PrEP What to do at the first visit? What to do at follow
More informationInternational Partnership for Microbicides
International Partnership for Microbicides Female-Initiated Prevention: State of the Art Dr. Zeda F. Rosenberg German-Austrian AIDS Congress Frankfurt, Germany 29 June 2007 Women s Vulnerability to HIV
More informationDrug development in relation to PrEP and the PROUD study
Drug development in relation to PrEP and the PROUD study David Dolling Medical Statistician MRC Clinical Trials Unit 18 th October 2012 What is PrEP? - Pre-exposure Prophylaxis A strategy that uses antiretrovirals
More informationTO DECREASE THE CHANCE OF GETTING
POST ASSAULT MEDICATIONS Terri Stewart RN Naomi Sugar MD TO DECREASE THE CHANCE OF GETTING Pregnant STDs Chlamydia Gonorrhea Trichomonas Hep B HIV EMERGENCY CONTRACEPTION Plan B Levonorgestrel PLAN B Plan
More informationPopulation attributable fraction of genital inflammation and ulceration in HIV risk among discordant couples, Zambia,
Population attributable fraction of genital inflammation and ulceration in HIV risk among discordant couples, Zambia, 1994-2012 10 th International Workshop on HIV Transmission Kristin M. Wall, PhD kmwall@emory.edu
More informationPrEP and npep for HIV Prevention. Harry Rosado-Santos MD, FACP Associate Professor UU School of Medicine
PrEP and npep for HIV Prevention Harry Rosado-Santos MD, FACP Associate Professor UU School of Medicine Case Study A 26 y/o M presents for routine asymptomatic screening for sexually transmitted infections
More informationAnswers to those burning questions -
Answers to those burning questions - Ann Avery MD Infectious Diseases Physician-MetroHealth Medical Center Assistant Professor- Case Western Reserve University SOM Medical Director -Cleveland Department
More informationRon Gray, MBBS, MFCM, MSc Johns Hopkins University. STIs in an International Setting
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationQUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE 1. What is the Partners PrEP study? The Partners PrEP Study is a double-blind,
More informationImplementing HIV Prevention in Patient Centered Medical Homes and Primary Care
A New Era of Highly-Effective HIV Prevention in Primary Care Part I Implementing HIV Prevention in Patient Centered Medical Homes and Primary Care Kevin Ard, MD, MPH and Harvey J Makadon, MD The Fenway
More informationCombination HIV Prevention
Combination HIV Prevention Timothy Mastro, MD, FACP, DTM&H FHI 360, Durham, North Carolina, USA 7 th INTEREST Workshop, Dakar, Senegal 15 May 2013 Outline What Works for HIV Prevention? Highly Active
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Diagnosis and promotion of serostatus awareness in sub-saharan Africa 1. Antiretroviral therapy reduces HIV transmission from a HIV- positive person to a susceptible
More informationStudy finds PEP not 100% effective in preventing HIV infection
From TreatmentUpdate 152 Study finds PEP not 100% effective in preventing HIV infection Some doctors and nurses who care for PHAs may sustain needle-stick injuries. This raises the possibility that they
More informationMANAGEMENT OF SEXUAL EXPOSURE TO HIV: PEPSE
Sandyford Protocols MANAGEMENT OF SEXUAL EXPOSURE TO HIV: PEPSE www.hiv-druginteractions.org If you require information on occupational exposure to blood borne viruses, including HIV, please refer to the
More informationPeople who experience gender based violence are more at risk of HIV.
Know the HIV risk People who experience gender based violence are more at risk of HIV. HIV Human Immunodeficiency Virus is the virus that causes AIDS by interfering with the body s ability to fight off
More informationM2010 Pre-Conference Workshop, Pittsburgh 22 May 2010
HIV Prevention Research: The Global Picture Presented at: M2010 Pre-Conference Workshop, Pittsburgh 22 May 2010 Salim S. Abdool Karim Pro Vice-Chancellor (Research): University of KwaZulu-Natal Director:
More informationHIV Prevention in US Women
HIV Prevention in US Women Sally L. Hodder M.D. Sally L. Hodder MD Professor of Medicine December 1, 2010 24, 2010 Overview Epidemiology of HIV in US women HIV testing Antiretroviral i treatment as HIV
More informationThe Latest on HIV Testing. Dominika Seidman, MD MAS
The Latest on HIV Testing Dominika Seidman, MD MAS Disclosures none 2 Learning objectives At the conclusion of this session, participants should be able to Define the window periods for various HIV tests
More informationAttendees will be able to:
A. Kay Kalousek, DO, MS, FACOFP kaysdroid@gmail.com April 21, 2017 Attendees will be able to: List strategies for prevention of HIV infection Explain the pharmacology of TDF/FTC related to PrEP Assess
More informationHIV & Condomless Sex - What is the Risk? Why Not? Alan J. Taege, MD Assistant Professor of Medicine Department of Infectious Disease Cleveland Clinic
HIV & Condomless Sex - What is the Risk? Why Not? Alan J. Taege, MD Assistant Professor of Medicine Department of Infectious Disease Cleveland Clinic Yes No What s Going on Out There? Condomless Sex among
More informationUpdate on PrEP progress: WHO/UNAIDS challenges and actions
Update on PrEP progress: WHO/UNAIDS challenges and actions Kevin R. O'Reilly Prevention in the Health Sector, HIV/AIDS Department, WHO HQ Outline Review current status of PrEP Planning for PrEP Pre-exposure
More informationPRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program
PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program Disclosures None Objectives Review the evidence regarding the
More informationHIV: A global perspective on epidemiology, diagnosis and prevention
HIV: A global perspective on epidemiology, diagnosis and prevention Margaret McLees, M.D., DTMH Instructor, Division of Infectious Diseases Denver Health University of Colorado November 13, 2012 Outline
More informationPre-exposure Prophylaxis for HIV Prevention
Mountain West AIDS Education and Training Center Pre-exposure Prophylaxis for HIV Prevention Concerns about PrEP: Sexual Behavior and STIs Joanne Stekler, MD MPH May 19, 2016 This presentation is intended
More informationWhere are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
More informationImportance of Viral Suppression to Reduce HIV Transmission: Recent Evidence
Importance of Viral Suppression to Reduce HIV Transmission: Recent Evidence Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine Viral suppression
More informationSTIs- REVISION. Prof A A Hoosen
STIs- REVISION Prof A A Hoosen Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria and the NHLS Microbiology Tertiary Laboratory at the Pretoria Academic Hospital Complex
More informationNursing Interventions
Chapter 16 H I Human Immunodeficiency V Virus A Acquired I Immuno D Deficiency S Syndrome Slide 1 Nursing Interventions Duty to treat Health care professionals may not pick and choose their patients Rehabilitation
More informationPage 1. Outline. Outline. Building specialized knowledge: HIV. Biological interactions. Social aspects of the epidemic. Programmatic actions
Harvard-Brazil Collaborative Public Health Field Course January 2014 Lecture # 8 Building specialized knowledge: HIV Aluisio Segurado Department of Infectious Diseases School of Medicine, University of
More informationARVs for prevention in at-risk populations: Microbicides
ARVs for prevention in at-risk populations: Microbicides Treatment as Prevention in Africa Meeting Botswana, April 30 May 3, 2014 Salim S Abdool Karim Director: CAPRISA Pro Vice-Chancellor (Research):
More informationClinical Education Initiative OCCUPATIONAL POST- EXPOSURE PROPHYLAXIS. Antonio E. Urbina, MD
Clinical Education Initiative Support@ceitraining.org OCCUPATIONAL POST- EXPOSURE PROPHYLAXIS Antonio E. Urbina, MD 5/22/2013 Occupational Post-Exposure Prophylaxis [Video Transcript] 00:00:15 - [Tony]
More informationAn International Antiviral Society-USA
Doug Campos-Outcalt, MD, MPA University of Arizona, Phoenix dougco@email.arizona. edu A look at new guidelines for HIV treatment and prevention Start antiretroviral therapy as soon as possible after HIV
More informationdetermine need but regimen does not change based on risk factor ED medicine attending meets
HIV PEP Guidelines after Sexual Assault Harborview Medical Center January 2015 Initial risk assessment and discussion with patient about risk and PEP is by clinician who does exam (SANE, Ob-Gyn resident,
More informationPrEP in the Real World: Clinical Case Studies
PrEP in the Real World: Clinical Case Studies Kevin L. Ard, MD, MPH April 30, 2015 Massachusetts General Hospital, National LGBT Health Education Center Continuing Medical Education Disclosure Program
More informationSTI s. (Sexually Transmitted Infections)
STI s (Sexually Transmitted Infections) Build Awareness In Canada and around the world, the trend is clear: sexually transmitted infections (STIs) are on the rise. One of the primary defenses in the fight
More informationGuidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft:
Guidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft: 10-2-2015 Clinical studies demonstrate that when a person without HIV infection takes
More informationPEP, PREP, HPTN052 and MLN2238
PEP, PREP, HPTN052 and MLN2238 Understanding the alphabet soup of HIV prevention and cure strategies Christina G Rivera, PharmD, BCPS Pharmacy Grand Rounds August 15, 2017 2017 MFMER slide-1 Presentation
More informationPre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection
Pre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection William F. Ryan Community Health Network PrEP Network Coordinator: Trevor Hedberg, MPH, CPH Supervising Health Educator:
More informationNon-Occupational Post-Exposure HIV Prophylaxis npep
Non-Occupational Post-Exposure HIV Prophylaxis npep Peter Meacher MD (Chief Medical Officer) Anthony Vavasis MD (Director of Medicine) Callen-Lorde Community Health Center Objectives - at the end of the
More informationHIV Prevention among Women
HIV Prevention among Women Assistant Professor of Medicine Division of Infectious Diseases Baylor College of Medicine Disclosures: Gilead Sciences - Scientific Advisory Board; Investigatorinitiated research
More informationOne of your office personnel
Doug Campos-Outcalt, MD, MPA Department of Family and Community Medicine, University of Arizona College of Medicine, Phoenix HIV postexposure prophylaxis: Who should get it? CORRESPONDENCE Doug Campos-Outcalt,
More informationAntiretrovirals for HIV prevention:
Antiretrovirals for HIV prevention: Topical PrEP, Systemic PrEP and Treatment for Prevention Presentation at 6th International workshop on HIV treatment, pathogenesis and prevention research in resource-limited
More informationSexually Transmitted Infections
Sexually Transmitted Infections STI Director/ Centers for Disease Control Overview Definition of STIs: What are they? Transmission: How are they spread? Types of infection: -Bacterial (Chlamydia, LGV,
More informationOn the Horizon for Consideration: Biomedical Advances in HIV Prevention
On the Horizon for Consideration: Biomedical Advances in HIV Prevention Francisco Ruiz, MS Senior Manager, National Alliance of State and Territorial AIDS Directors New Jersey Governor's Advisory Council
More informationPre-exposure Prophylaxis (PrEP) Non-occupational Post-exposure Prophylaxis (npep) Jeffrey Beal, MD, AAHIVS Florida Health Lee County
Pre-exposure Prophylaxis (PrEP) Non-occupational Post-exposure Prophylaxis (npep) Jeffrey Beal, MD, AAHIVS Florida Health Lee County Division of Disease Control and Health Protection To protect, promote
More informationPREP IN PRIMARY CARE TRACY SALAMEH RN, BSN, ACRN HIV CLINICAL SPECIALIST DAKOTA AIDS EDUCATION AND TRAINING CENTER
PREP IN PRIMARY CARE TRACY SALAMEH RN, BSN, ACRN HIV CLINICAL SPECIALIST DAKOTA AIDS EDUCATION AND TRAINING CENTER THE NEED FOR CONTINUED HIV PREVENTION Estimated new HIV infections in the US for the most
More informationHIV In South Africa: Turning the Tide of the Epidemic
HIV In South Africa: Turning the Tide of the Epidemic Jean B. Nachega, MD, PhD Associate Professor Department of Epidemiology Pittsburgh University, Graduate School of Public Health E-mail: JBN16@PITT.EDU
More informationHIV PREP THE NEWEST TOOL IN THE BOX
HIV PREP THE NEWEST TOOL IN THE BOX Infectious Disease Update November 7, 2014 Andrew Petroll, MD, MS Department of Medicine, Division of Infectious Diseases Department of Psychiatry and Behavioral Medicine,
More information8/25/2016. Making Preexposure Prophylaxis Available in the Clinic: Considerations and Pathways Forward
WORKSHOP SESSION: MAKING PREEXPOSURE PROPHYLAXIS AVAILABLE IN THE CLINIC: CONSIDERATIONS AND PATHWAYS FORWARD PRE-REGISTRATION IS REQUIRED PLEASE SEE THE CPT INFORMATION DESK IF THIS IS NOT YOUR SELECTED
More informationSexually Transmitted Infections (STIs)
Sexually Transmitted Infections (STIs) Overview Definition of STIs: What are they? Transmission: How are they spread? Types of infection: Bacterial (Chlamydia, Gonorrhea, Syphilis) Viral (Hepatitis B,
More informationSouth African Guidelines for the Safe Use of. Dr. Oscar Radebe
South African Guidelines for the Safe Use of PrEP in MSM Dr. Oscar Radebe Background Globally MSM(men who have sex with men) have been disproportionately at high risk of HIV transmission. Biological &
More informationLooking at NY: Our rate of chlamydia is higher than the US as a whole; we rank 13th among all states.
1 In this presentation, we will discuss: What are the most common STDs in NYS What are the most common STDs Can I get gonorrhea from oral sex How do you know if you/or your partner has an STD? Does getting
More informationInternational Partnership for Microbicides
International Partnership for Microbicides Advancing HIV Prevention Options for Women GNP+ Consultation on NPTs Thomas Mertenskoetter 5. 6. July 2010, Amsterdam Leading Causes of Death in Women (Age 15
More informationProfessor Adrian Mindel
Causes of genital ulceration viruses and others Professor Adrian Mindel University of Sydney VIM 16 th August 2012 Outline Definition Causes Epidemiology Diagnosis Definition of genital ulcer A defect
More informationPrEP Dosing Strategies
PrEP Dosing Strategies Outline o Background PrEP absorption and tissue penetration o Oral versus topical o Lead in and lead out dosing Time to protection o Cycling on and off PrEP o Balancing toxicity
More informationSTIs and BBVs. The facts
EASY ENGLISH STIs and BBVs Some people say sex germs The facts New words There may be words in this factsheet that are new to you and you may not know what they mean or you may be unsure what they mean.
More informationReady, set, PrEP! Renee-Claude Mercier PharmD, PhC, BCPS-AQ ID, FCCP Professor of Pharmacy and Medicine University of New Mexico
Ready, set, PrEP! Renee-Claude Mercier PharmD, PhC, BCPS-AQ ID, FCCP Professor of Pharmacy and Medicine University of New Mexico Objectives At the end of the talk the audience should be able to: Understand
More informationUpdated Guidelines for Post-Assault Testing and Treatment
Updated Guidelines for Post-Assault Testing and Treatment Ann S. Botash, MD Professor of Pediatrics October 5, 2016!" Disclosure Statement Ann S. Botash, MD, has no financial relationships with any commercial
More information